The Rodman & Renshaw Annual Global Investment Conference takes place November 10, 2008 – November 12, 2008 at the New York Palace Hotel in New York. Listed below are the Rodman & Renshaw Annual Global Investment Conference presenter profiles. For in-depth information about the event, visit http://www.rodmanandrenshaw.com/conferences?id=19
Business Wire is the official news wire for the Rodman & Renshaw Annual Global Investment Conference. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire’s trade show, conference, and event news resource.
Company: 4SC AG Ticker Symbol & Exchange: VSC / Xetra Investor Relations Contact: Bettina von Klitzing Investor Relations Contact Phone: 49-89-700 763 0 Web: www.4sc.com Date of Presentation: November 10th, 2008 4SC AG develops innovative drug candidates against inflammatory diseases and cancer. 4SC AG utilises its proprietary technology platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical proof of concept in early clinical phases. There are currently eight projects in development. A clinical phase IIa for the treatment of rheumatoid arthritis has already successfully been completed. An additional project for the treatment of various cancers is currently completing a clinical phase I trial. The company is listed at the Prime Standard of Frankfurt Stock Exchange since December 2005. Company: Aastrom Biosciences, Inc. Ticker Symbol & Exchange: NASDAQ: ASTM Investor Relations Contact: Kris M. Maly/Kimberli O'Meara Investor Relations Contact Phone: (734) 930-5777 Web: www.aastrom.com Date of Presentation: 11/11/2008; 5:20 PM-5:45 PM Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. Aastrom's Tissue Repair Cell (TRC) based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. The Company is currently focused on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial). Company: Access Pharmaceuticals, Inc. Ticker Symbol & Exchange: ACCP.OB Investor Relations Contact: Stephen B. Thompson Investor Relations Contact Phone: 214-905-5100 Web: www.accesspharma.com Date of Presentation: Tuesday, November 11, 2008 Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, MuGard(TM) for the management of oral mucositis that is partnered globally, and should commence sales in 4Q08. The company's lead oncology product is ProLindac(TM), a polymer-linked platinum cancer drug, which is in Phase 2 clinical testing in recurrent ovarian cancer patients. Angiolix(R) an antiangiogenic humanized monoclonal antibody, and Thiarabine, a novel nucleoside in trials in leukemia, are the company's lead oncology products. Access is also developing oral insulin and oral hGH using its proprietary Cobalamin(TM) oral drug delivery technology. Company: Action Energy Inc. Ticker Symbol & Exchange: AEC - TSX-V Investor Relations Contact: Mr. Kelly D. Kerr - VP Finance Investor Relations Contact Phone: (403) 723-4454 Web: www.action-energy.com Date of Presentation: 11/10/2008 Action Energy Inc. is a Calgary Alberta based junior oil and natural gas exploration company focused on exploring the western Canadian sedimentary basin for properties with significant production and reserve potential. Action was incorporated in 2000 and to date has quickly grown to a company producing 1,500 - 1,600 boed through a combination of exploration and development drilling and mergers and acquisitions. The Company has a portfolio mainly consisting of light oil properties focused on the Bakken and Midale plays in southeast Saskatchewan, heavy oil in the Lloydminster area of central Alberta and sweet natural gas properties in the Peace River Arch area of northwest Alberta. Action has captured large concentrated undeveloped land positions with high working interests in its primary plays giving the Company large upside potential. Company: Active Biotech AB Ticker Symbol & Exchange: ACTI; OMX Nordic Investor Relations Contact: Mr Goran Forsberg Investor Relations Contact Phone: +46 46 19 11 54 Web: www.activebiotech.com Date of Presentation: 11/11/2008 Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(R) for RA. Please visit www.activebiotech.com for more information. Company: Acucela Inc. Investor Relations Contact: Sayuri Refsland Investor Relations Contact Phone: 425-527-3272 Web: www.acucela.com Date of Presentation: 11/12/2008 Acucela Inc. is a clinical-stage biotechnology company focused on developing new drug therapies for blinding eye diseases such as age- related macular degeneration (AMD), Stargardt disease, diabetic retinopathy and retinopathy of prematurity, as well as dry eye. The most advanced product candidate of our developing compounds, Rebamipide ophthalmic suspension, is currently in Phase III clinical trials for dry eye and is being co-developed with Otsuka Pharmaceutical in the U.S. We are also conducting a Phase I clinical trial of ACU-4429 for dry age-related macular degeneration (AMD), which is also being co-developed with Otsuka Pharmaceutical. Company: Adanac Molybdenum Corporation Ticker Symbol & Exchange: AUA & Frankfurt A9N Investor Relations Contact: Connie Fischer/Peter Jones Investor Relations Contact 604.531.9639 or 604.535.6834 Phone: Web: www.adanacmoly.com Date of Presentation: 11/11/2008 Adanac Molybdenum Corporation is listed on the TSX and Frankfurt exchanges and owns the Ruby Creek Molybdenum Project in Northern British Columbia. The Company has advanced the project through feasibility studies, a production decision and has previously ordered $137 million of long-lead equipment, completed permitting for construction, constructed a road to the site and secured US$80 million in bridge financing. The Company is sourcing final construction funding and expects a site construction start in February 2009 and production in Q4, 2010. The mine will be the world's first new large scale molybdenum open pit mine in more than 25 years. Company: AgFeed Industries, Inc. Ticker Symbol & Exchange: FEED (NASDAQ) Investor Relations Contact: Mr. Gerry Daignault Investor Relations Contact Phone: 615-480-7847 Web: www.agfeedinc.com Date of Presentation: 11/10/2008 9:55 AM AgFeed Industries, Inc. a US public company is the largest commercial hog producer and the largest premix feed company in China. With over 600 million hogs produced each year, compared to 100 million in the US, China represents more than 50% of the world's annual hog production as well as the world's largest and most profitable pork consumer markets. We are a strategic platform for accessing China's vast feed and hog raising industries. The pre-mix feed market in which AgFeed operates is an approximately $1.6 billion segment of China's $40 billion per year animal feed market. Company: Alberta Oilsands Inc. Ticker Symbol & Exchange: AOS Web: www.aboilsands.ca Date of Presentation: November 12, 2008 at 10:20am Alberta Oilsands Inc. (TSX-V: AOS) is a junior oil sands development company focused in the Athabasca oil sands region of northeast Alberta. The Company has acquired 89,920 gross (77,568 net) acres of prospective oil sands leases on the primary oil sands fairway. AOS's strategy is to take advantage of its proven oil sands experience to delineate and prove up bitumen reserves sufficient to support a minimum 10,000 barrel per day in-situ project by 2012. The company has four project areas, namely Clearwater, Hangingstone, Algar lake and Grand rapids which in aggregate hold nearly 5 billion barrels of bitumen in place. The Clearwater delineation drilling program in Q1-2009 provided the company with 320 million barrels of contingent recoverable bitumen resource over just 2800 acres and potentially two 10,000 barrels per day projects Company: Alhambra Resources Ltd. Ticker Symbol & Exchange: ALH - TSX Venture Investor Relations Contact: Ihor P. Wasylkiw Investor Relations Contact Phone: 1 (403) 508-4953 Web: www.alhambraresources.com Date of Presentation: Tuesday, Nov 11/08 @ 2:50 PM EST Alhambra is a Canadian based international exploration and gold production Corporation, celebrating its 7th year of operations in the Republic of Kazakhstan. Alhambra holds exploration and exploitation rights to a 2.7 million acre, 100% owned, property called the Uzboy Project, located in the prolific Charsk Gold Belt which hosts numerous world-class gold deposits. Alhambra is currently producing gold and has 14 years remaining of a 25 year license which is renewable for an additional 20 years and allows the Corporation to explore for all metals including gold, base metals, uranium and molybdenum. Company: Allon Therapeutics Inc. Ticker Symbol & Exchange: TSX:NPC Investor Relations Contact: Aaron Keay Investor Relations Contact Cell: (604) 323-6911, D: (604) 742- Phone: 2540 Web: www.allontherapeutics.com Date of Presentation: Monday, November 10, 2008 - 9:30am ET Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead clinical program is focused on Alzheimer's disease. In February 2008 the Company announced positive results in a Phase IIa clinical study for amnestic MCI, a precursor to Alzheimer's disease, showing statistically significant, dose dependant, and durable efficacy on human memory. The Company also has a Phase II trial underway in schizophrenia cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver. Company: Allos Therapeutics, Inc. Ticker Symbol & Exchange: NASDAQ: ALTH Investor Relations Contact: Derek Cole Investor Relations Contact Phone: 720.540.5367 Web: www.allos.com Date of Presentation: Tuesday, November 11, 2008 Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company expects to report top line results of the PROPEL trial by the end of 2008. The Company is also investigating PDX in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma subtypes. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma (NHL). Allos currently retains exclusive worldwide rights to PDX and RH1. Company: Alphatec Spine Ticker Symbol & Exchange: ATEC Investor Relations Contact: Cheryl Monblatt Investor Relations Contact Phone: 760 494 6746 Web: www.alphatecspine.com Date of Presentation: Monday, November 10 Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, The Company also markets its spine products in Europe. Company: Amarin Corporation Ticker Symbol & Exchange: AMRN (Nasdaq) Investor Relations Contact: Darren Cunningham Investor Relations Contact Phone: 35316699020 Web: www.amarincorp.com Date of Presentation: 11/11/08 Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Company: American Lorain Corporation Ticker Symbol & Exchange: ALRC.OB Investor Relations Contact: CCG Investor Relations Investor Relations Contact Crocker Coulson, 646-213-1915 Phone: Web: www.lorainfood.com Date of Presentation: November 10th at 3:15 pm ET American Lorain Corp. is a major processed foods company located in China. The Company commenced operations of Shandong Lorain, its first operating subsidiary, in 1995, to manufacture chestnut products and over years, it expanded its product lines to include canned, frozen and bulk foods, and convenience foods sold to domestic and international customers. The Company now has four manufacturing facilities. In the highly fragmented processed foods industry, Lorain has gained competitive advantages through its proprietary brands and advanced technologies and currently sells over 192 products to19 provinces and administrative regions in China as well as to 42 foreign countries. Company: American Tony Pharmaceuticals Inc Ticker Symbol & Exchange: OTC BB/ATNY.OB Investor Relations Contact: Leslie Wolf-Creutzfeldt Investor Relations Contact Phone: 646-284-9472 Web: www.tmyy.com.cn Date of Presentation: Nov 12 at 9:30am Tongli Pharmaceutical (USA), Inc. develops, manufactures and markets pharmaceutical and health care products through its wholly-owned subsidiary, Harbin Tianmu Pharmaceutical Co., Ltd. ("Tianmu Pharmaceutical"). Tianmu Pharmaceutical was founded in 1999 in Harbin, hub of the Northern Pharmaceutical base of China. The company acquired the GMP certificate in 2003 and was listed on the OTC Bulletin Board on July 29, 2008. With a cohesive management team and committed staff, Tongli is providing the best quality pharmaceutical products at a very competitive price. The company is targeting the vast Chinese market with a vision of extending its footprint to East Asia and Russia. Company: Anadis Limited Ticker Symbol & Exchange: ASX: ANX Investor Relations Contact: Dr. Oren Fuerst Investor Relations Contact Phone: 646 259 3321 Web: www.anadis.com Date of Presentation: 11/12/2008 Anadis is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Anadis' proprietary and low-cost antibody manufacturing technology enables it to rapidly develop polyclonal antibody and other protein-based oral therapies to a range of important infectious and immune- mediated diseases. Large target markets with products reaching the markets in 2-3 years, all using the same platform. -- Cancer therapy-related Mucositis (clinical trial in Israel started) -- HIV/AIDS (major clinical trial in Australia just announced) -- Diabetes (clinical trial to be initiated within a few months pending a transaction) -- Influenza (clinical trial to begin during the year) Commercial products : E.coliTravelers' Diarrhea and Rotavirus infection Company: Argentex Mining Corporation Ticker Symbol & Exchange: TSX-V:ATX;OTCBB:AGXM Investor Relations Contact: Primoris Group Inc. Investor Relations Contact Phone: 1-866-594-7687 Web: www.argentexmining.com Date of Presentation: Tues. November 11, 2008, 11:10 a.m. Argentex Mining Corporation is a junior mining exploration company with extensive holdings in Argentina's Patagonia region, including its flagship Pinguino property in Santa Cruz province. The company holds 100% mineral rights to this property, which has a unique commodity profile: gold, silver, lead, zinc and indium. Argentex's exploration team has taken Pinguino from the grassroots stage to a significant drill-tested deposit (30,000+ meters completed) in just a few years. Argentex also owns 100% mineral rights to more than 30 properties with over 377,490 acres (152,766 hectares) of prospective land located in Argentina's Santa Cruz and Rio Negro provinces. Company: Arrow Energy Limited Ticker Symbol & Exchange: AOE.AX (ASX) Investor Relations Contact: Graham Yerbury Investor Relations Contact Phone: +61 7 31053466 Web: www.arrowenergy.com.au Date of Presentation: Monday November 10, 2008 Arrow Energy is an ASX 100 listed Coal Bed Methane Company operating in Australia and South East Asia. Arrow's Australian tenements are estimated to have 70Tcf of gas in place. Arrow and it's joint venture partner Shell are moving towards developing the world's first CBM to LNG operation in the Gladstone port with initial plans for a 1.5mtpa plant in operation by 2012. Arrow has also integrated downstream into the production of electricity with access to 370MW of electricity offtake. Arrow is currently completing exploration and appraisal activity in India and Vietnam with business development opportunities in China and Indonesia. Company: Asia Time Corporation Ticker Symbol & Exchange: Amex: TYM Investor Relations Contact: Brandi Floberg Investor Relations Contact Phone: 310-277-4711 Web: www.asiatimecorp.com Date of Presentation: November 10, 2008 at 10:20 a.m. ET Asia Time is a Hong Kong distributor of timepiece movements. The Company currently distributes approximately 350 products, including both watch movements and complete watches, representing 30 vendors. These products are supplied to Asia Time's more than 300 customer manufacturers of globally branded watches. The Company's distribution centers and sales offices are located throughout Hong Kong and China. Asia Time is well positioned to capitalize on growth opportunities in developed markets and especially in the under-penetrated market for watch movements and completed watches in China. The Company holds strong competitive advantages in quartz and mechanical movements, and it seeks to expand up the watch market value chain into low-cost China-based manufacturing of proprietary branded movements and complete watches. Company: Aurora Oil & Gas Limited Ticker Symbol & Exchange: "AUT" on ASX Investor Relations Contact: Jon Stewart (Exec Chairman) Investor Relations Contact [email protected], 61 89440 Phone: 2626 Web: www.auroraoag.com.au Date of Presentation: 11/10/2008 Aurora Oil & Gas Limited is an Australian quoted public company (ASX: AUT) focused in North America. Aurora participates in advanced exploration/development opportunities with large size potential. Aurora's principal asset is its substantial landholdings in the recently discovered Sugarkane Field in South Texas. Sugarkane Field is a potential multi TCFe gas and condensate resource. The Sugarkane Field was discovered in 2006 with an exploration well that intersected a unique over pressured, porous condensate rich Austin Chalk formation within the region. Several follow up wells have been successfully drilled and appraisal and development drilling of this field is under way. Company: Ausam Energy Corporation Ticker Symbol & Exchange: AZE.V, ASMEF.OB Investor Relations Contact: Mark G. Avery Investor Relations Contact Phone: 1.863.678.2200 Web: www.ausamenergy.com Date of Presentation: 11/11/2008 Ausam is a public company engaged in oil and gas exploration and development. Ausam, through its U.S. subsidiary Noram Resources, Inc, has acquired a diverse portfolio of oil and gas leases and prospects in Texas, Louisiana, Mississippi, Alabama and Arkansas. Ausam's growth strategy includes the systematic development of its current holdings and selective corporate transactions. The Company trades under the symbol "AZE" on the TSX Venture Exchange and the symbol "ASMEF" on the OTC Bulletin Board Company: Avanir Pharmaceuticals Ticker Symbol & Exchange: AVNR / NASDAQ Investor Relations Contact: Eric Benevich Investor Relations Contact Phone: (949)389-6776 Web: www.avanir.com Date of Presentation: November 11, 2008 at 4:55pm ET AVANIR Pharmaceuticals is a biopharmaceutical company focused on developing novel treatments for central nervous system conditions. AVANIR's lead product candidate, Zenvia(TM), is in Phase III development for two indications; pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. Zenvia is the subject of an approvable letter from the FDA for the PBA indication. The Company is now conducting a confirmatory Phase III study testing a lower dose formulation intended to improve safety and tolerability. Top line results are expected in Q3 of 2009. Please review AVANIR's SEC filings or www.avanir.com for further information regarding risks and uncertainties affecting the Company. Company: Bio-Bridge Science, Inc. Ticker Symbol & Exchange: BGES - OTCBB Investor Relations Contact: Chris Young Investor Relations Contact Phone: (630) 928-0869 Web: http://www.bio-bridge-science.com Date of Presentation: 11/12/2008 Bio-Bridge Science is a biotechnology company engaged in the commercial development of vaccines and related products for the prevention and treatment of human diseases. The company is currently developing oral vaccines against HIV, HPV and colon cancer. In addition, the Company has a subsidiary that produces bovine serum and plans to form a joint venture to produce cell culture medium for vaccine production. Company: BioDelivery Sciences International Ticker Symbol & Exchange: BDSI (NASDAQ) Investor Relations Contact: Bryan Armstrong Investor Relations Contact Phone: 312-553-6707 Web: [email protected] Date of Presentation: Mon. November 10, 2008 at 10:20 am BioDelivery Sciences is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships, new applications of proven therapeutics. The development strategy focuses on the utilization of the FDA's 505(b)(2) approval process to obtain timely and efficient approval of new formulations of previously approved therapeutics which incorporate the company's drug delivery technologies, BioErodible MucoAdhesive (BEMA) and Bioral. BDSI is addressing important unmet market needs with a focus on formulations of pharmaceuticals aimed principally at treatment opportunities in areas such as pain and fungal infections. The company's lead product ONSOLIS (BEMA Fentanyl) is currently under review at FDA with an anticipated approval 1H 2009. Company: BioSante Pharmaceuticals, Inc. Ticker Symbol & Exchange: BPAX NASDAQ Investor Relations Contact: Phillip Donenberg Investor Relations Contact 847-478-0500 ext 100 Phone: Web: www.biosantepharma.com Date of Presentation: 11/12/2008 BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T- Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Company: Boots & Coots Ticker Symbol & Exchange: NYSE Alternext: WEL Investor Relations Contact: Jennifer Tweeton Investor Relations Contact Phone: 281-931-8884 Web: www.boots-coots.com Date of Presentation: November 11, 10:45 am Eastern Boots & Coots provides a suite of integrated pressure control services to oil and gas exploration companies around the world. Our services are designed to enhance production and reduce the number and severity of critical well events such as well fires, blowouts or other losses of control at the well. Our Well Intervention segment includes services performed by hydraulic workover and snubbing units and the rental of pressure control tools. This segment also includes prevention and risk management services offered through our Safeguard and risk mitigation programs. Our Response segment consists of personnel, equipment and services provided during a critical well event. Company: BPZ Energy Ticker Symbol & Exchange: NYSE Alternext:BPZ Investor Relations Contact: Greg Smith Investor Relations Contact Phone: 281 752 1240 Web: www.bpzenergy.com Date of Presentation: 11/10/2008 Houston based BPZ Energy is an oil and gas exploration and production company which has exclusive license contracts for oil and gas exploration and production covering approximately 2.4 million acres in four properties in northwest Peru. It also owns a minority working interest in a producing property in southwest Ecuador. The Company is currently executing the development of the Corvina oil discovery, the redevelopment of the Albacora oil field, and the exploration of Block XIX, in parallel with the execution of an integrated gas-to-power strategy, which includes generation and sale of electric power in Peru and the development of a regional gas marketing strategy. The Company's website at www.bpzenergy.com provides additional information about the Company's plans, including photographs and other information with respect to its operat Company: Bradmer Pharmaceuticals Inc. Ticker Symbol & Exchange: BMR (TSX) Investor Relations Contact: Ross Marshall, Equicom Group Investor Relations Contact 416-815-0700 x238 Phone: Web: http://www.bradmerpharma.com Date of Presentation: 11/12/08, 10:45 a.m. Bradmer Pharmaceuticals is a biopharmaceutical company established in 2006 to advance a promising new drug for glioblastoma multiforme patients into a pivotal Phase III trial. Neuradiab(TM) (formerly referred to as "I-131 mu81C6" in scientific literature) is a radiolabeled monoclonal antibody that has been delivered to more than 200 patients in its significant Phase I and II clinical history at Duke University. It has been designed to deliver a precise localized radiation boost dose specifically to post-surgical residual cancer cells via single injection. Our multi-center randomized trial for patients with newly-diagnosed GBM is underway at leading brain tumor treatment centers across the US. This Phase III trial will investigate Neuradiab as an adjuvant therapy to surgery, external beam radiation and temozolomide. Company: Bravo Venture Group Inc. Ticker Symbol & Exchange: BVG-TSX.Venture Investor Relations Contact: Jay Oness Investor Relations Contact Phone: 1-888-456-1112/604-641-2771 Web: www.bravoventuregroup.com Date of Presentation: Tuesday, November 11th at 2:25pm The company is active in NW British Columbia, Alaska and Nevada. The VMS/Epithermal gold/silver Homestake Ridge project in BC is advancing with excellent drill results and an NI43-101 compliant technical report (being updated) which reported an inferred resource of +900,000 oz/Au. Recent certified assays from the now completed 8,400 metre drill program returned BONANZA grade intercepts;73metres averaging 21g/t gold with an intercept of 7.65metres averaging 181.58 g/t gold, as well, another intercept recorded 22.29metres of 513.7 g/t silver including a 2.71metre bonanza grade averaging 2,502 g/t silver. Other project include the VMS Woewodski Island project in Alaska and 13 projects in Nevada. Company: CanAlaska Uranium Ltd Ticker Symbol & Exchange: TSX.V: CVV Investor Relations Contact: Emil Fung, V.P. Corp. Dev. Investor Relations Contact Phone: 604 688 3211 Web: www.canalaska.com Date of Presentation: Tuesday, November 11th 2008 @ 14:00 CANALASKA URANIUM LTD. (CVV -- TSX.V) is undertaking uranium exploration in nineteen 100%-owned and two optioned uranium projects in Canada's Athabasca Basin, supplier of 30% of the world's uranium and home to the planet's richest uranium mines. Since September 2004, the Company has aggressively acquired one of the largest land positions in the region, comprising over 2,500,000 acres (10,117 sq. km or 3,906 sq. miles). To-date, CanAlaska has expended over Cdn$45 million and has delineated multiple uranium targets. The company is financially-supported by numerous strategic partners, including, Mitsubishi Development Pty, a subsidiary of Japanese conglomerate Mitsubishi Corporation, and a consortium of leading Korean energy companies comprising Hanwha Corp., KEPCO, KORES and SK Energy. Company: Candax Energy Inc. Ticker Symbol & Exchange: CAX: TSX Investor Relations Contact: Lindsay Carpenter Investor Relations Contact [email protected], 416-868-1079 ext. Phone: 239 Web: www.candax.com Date of Presentation: 11/11/2008 Candax Energy Inc. is a Canadian based oil and natural gas company engaged in the exploration, acquisition, development and production of crude oil and natural gas, with emphasis on Africa and the Middle East. Candax has three producing fields in Tunisia: offshore at El Bibane, and onshore at Ezzaouia and Robbana and significant upside potential through its Deep Triassic play, its onshore Chaal gas discovery and its promising early exploration work in Madagascar. Candax's net production for Q3 is expected to average 1,600 boepd (1,200 bopd and 2 MMcf/d) and production for Q4 is forecast at 2,800 boepd (2,000 bopd and 4.7 MMcf/d). Company: CAS Medical Systems, Inc. Ticker Symbol & Exchange: CASM Investor Relations Contact: Susan Carron Investor Relations Contact Phone: 203-488-6056 Web: www.casmed.com Date of Presentation: 11/12/2008 CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition. The Company's product lines also include bedside patient vital signs monitors, proprietary non-invasive blood pressure measurement technology, blood pressure cuffs and products for neonatal intensive care. Company: Cavico Corp. Ticker Symbol & Exchange: OTCBB: CVIC Investor Relations Contact: Roger Ellis Investor Relations Contact Tel: 310-477-9800 Ext 106 Phone: Web: www.cavicocorp.com Date of Presentation: 11/11/2008 Cavico Corp. is a major infrastructure contractor with over 3,000 employees, including 700 engineers. Headquartered in Hanoi, Vietnam, Cavico operates nationwide in Vietnam with an expanding global presence through direct and indirect subsidiaries. Cavico is the only firm using the latest Tunnel Boring Machine (TBM) Technology in Vietnam. As an essential participant in the development of Vietnam's infrastrcuture to support Asia's second highest growth rate, Cavico has a focus on large construction projects for hydropower facilities, dams, bridges, tunnels, roads, and mines. Cavico also participates in ownership investments related to its core competency in energy, mining, cement plants, and urban development companies. Company: Celsion Corporation Ticker Symbol & Exchange: NASDAQ: CLSN Investor Relations Contact: Geoffrey Grande, CFA Investor Relations Contact Phone: 617-747-1721 Web: http://www.celsion.com/ Date of Presentation: Nov. 11th, from 4:30 to 4:55 PM Celsion Corporation is an oncology drug development company focused on addressing cancers of high unmet medical needs. The proprietary drug platform - heat activated liposomal technology - effectively targets high concentrations of chemotherapeutics to organs of interest. The lead drug candidate - ThermoDox - is currently in global Phase III trials for liver cancer in 7 countries. Additional drug candidates - liposomal docetaxel and liposomal carboplatin - are currently in preclinical development. Celsion has research, license or commercialization agreements with leading institutions such as the NIH-NCI, Philips, Duke, University of Hong Kong, Cleveland Clinic, North Shore-LIJ, and 40 other leading medical institutions worldwide. Company: China Armco Metals, Inc. Ticker Symbol & Exchange: OTC BB: CNAM Investor Relations Contact: HC International, Inc. Investor Relations Contact Alan Sheinwald, 914-669-5340 Phone: Web: www.armcometal.com Date of Presentation: 11/10/2008 China Armco Metals, Inc. imports, sells, distributes metal ores and non-ferrous metals throughout the PRC. Armco is also ennted into the metal recycling business. The Company's product lines include ferrous and non-ferrious ore such as iron ore, chrome ore, nickel ore, copper ore, magnese ore and steel billet. Raw materials are supplied from global suppliers in India, Hong Kong, Nigeria, Brazil, Turkey, the Philippines and Libya. Beginning in the second quarter 2009, Armco expects to begin operations in its steel recycling and scrap metal supply. The recycling facility is expected to be capable of recycling one million metric tons of scrap metal per year which will position the Company as one of the top 10 recyclers of scrap metal in China. Company: China Direct, Inc. Ticker Symbol & Exchange: NASDAQ: CDS Investor Relations Contact: Lillian Wong Investor Relations Contact 954.363.7333 ext. 317 Phone: Web: www.ChinaDirectInc.com Date of Presentation: 11/10/2008 China Direct is a diversified management and advisory services organization which owns and consults business entities operating in the People's Republic of China. We operate two divisions: Management Services and Advisory Services. Our Management Services division acquires controlling interests of Chinese business entities. Our Advisory Services division provides consulting services to both Chinese entities seeking access to the U.S. capital markets and North American entities seeking business opportunities in the PRC. As a direct link to China, China Direct serves as a vehicle allowing investors to participate directly in the rapid growth of the Chinese economy. For more information, please visit www.ChinaDirectInc.com. Company: China Green Agriculture Inc. Ticker Symbol & Exchange: CGAG.OB Investor Relations Contact: Ying Yang Investor Relations Contact Phone: 626-623-2575 Web: www.cgagri.com Date of Presentation: 11/12/2008 China Green Agriculture, through its wholly-owned subsidiary Shaanxi TechTeam Jinong Humic Acid Product Co., Ltd, develops, manufactures and distributes humic acid-based liquid compound fertilizers in 27 provinces throughout China. The Company offers over 100 different varieties of fertilizers targeted to unique climate and soil specifications. China Green Agriculture's headquarters, based in Shaanxi Province, include extensive R&D facilities and cutting edge automated production lines. With one of the most recognizable brand names in Chinese green fertilizers today, the Company is one of the few fertilizer manufacturers in China that operates on a national scale. Company: China Marine Food Group, Ltd. Ticker Symbol & Exchange: OTC BB: CMFO Investor Relations Contact: HC International, Inc. Investor Relations Contact John Mattio, 914-669-5340 Phone: Web: www.china-marine.cn Date of Presentation: 11/10/2008 Founded in 1994, China Marine Food Group, Ltd. processes and distributes processed seafood snack-type products, fresh and frozen marine catch to five provinces in the PRC and select international markets. Since inception, China Marine has grown steadily, received "The Famous Brand" and "Green Food" awards, and positioned its "Mingxiang"brand as a category leader in 1,300 retail sales points in the PRC. The Company is committed to the highest standard of quality control and is strategically located in Fujian Province, one of the largest coastal provinces in the PRC and a vital navigation hub bewteen the East China Sea and the South China Sea. For the first six months ended June 30, 2008, revenue and net income increased 35.9% and 39.2% to $23.8 million and $6.0 million respectively. Company: China North East Petroleum Holdings Ltd. Ticker Symbol & Exchange: CNEH OTCBB Investor Relations Contact: Chao Jiang Investor Relations Contact Phone: 212-307-3568 Web: www.cnepetroleum.com Date of Presentation: 11/12/2008 China North East Petroleum Holdings Limited (OTCBB: CNEH), through its subsidiaries, engages in the extraction and production of crude oil in Northern China. The company was founded in 2002 and is based in Harbin China and New York. The company owns 20 years leasing rights in Jilin Qian'an Oil Field, an oil field located approximately 9 kilometers southwest of Qian'an city Jilin Province China with a total exploration area of approximately 11,663 acres. The Company has a guaranteed arrangement with the Jilin Refinery of PetroChina to sell its produced crude oil for use in the China marketplace. China North East Petroleum currently has about 312 employees and 214 wells within four oilfields in Northern China and has plans for additional well drilling projects. Company: China Wind Systems, Inc. Ticker Symbol & Exchange: CWSI.OB Investor Relations Contact: Crocker Coulson Investor Relations Contact Phone: (646) 213-1915 Date of Presentation: 4:05 p.m. 11th November 2008 China Wind Systems, Inc. supplies forged rolled rings to the wind power and other industries and industrial equipment to the textile and energy industries in China. With its newly finished state-of- the-art production facility, the Company is expected soon to significantly increase its shipment of high- precision rolled rings and other essential components primarily to the wind power and other industries. Company: China Yingxia International, Inc. Ticker Symbol & Exchange: CYXI.OB Investor Relations Contact: CCG Investor Relations Investor Relations Contact Crocker Coulson, 646-213-1915 Phone: Web: www.chinayingxia.com Date of Presentation: November 12th at 10:45 am China Yingxia International, Inc. is primarily engaged in the development, production and sales of health food products in China. The Company sells over 235 stock keeping units (SKUs) in five product categories including soybean-based food and drinks, Longgu golden millet enriched products, raw cacti, cactus-based herbal supplements, personal care products, Nestle products and organic rice products. Yingxia was founded in 1998 and is headquartered in Harbin, Heilongjiang province, People's Republic of China. Company: ChinaCast Education Corporation Ticker Symbol & Exchange: CAST - NASDAQ Investor Relations Contact: Michael Santos Investor Relations Contact Phone: 202-361-3403 Web: www.chinacasteducation.com Date of Presentation: Nov. 10, 2008 ChinaCast Educations Corporation is a leading for-profit, post- secondary education and e-learning services provider in China. We provide fully accredited four year degree and two year diploma post- secondary education programs through our university in Chongqing, the Foreign Trade and Business College (FTBC) of Chongqing Normal University. We provide our e-learning services to post-secondary institutions, K-12 schools, government agencies and corporations via our nationwide satellite broadband network. These services include interactive distance learning applications, multimedia education content delivery, English language training and vocational training courses. Company: Cipher Pharmaceuticals Inc. Ticker Symbol & Exchange: DND: TSX Investor Relations Contact: Craig Armitage Investor Relations Contact (416) 815-0700 x278 Phone: Web: www.cipherpharma.com Date of Presentation: 11/12/2008 Cipher Pharmaceuticals is an emerging specialty pharmaceutical company with a late-stage product portfolio. The Company is focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America (formerly ProEthic Pharmaceuticals) under the label Lipofen(R). In addition, Cipher is developing novel formulations of the pain reliever tramadol and the acne treatment isotretinoin. Company: Clinuvel Pharmaceuticals Limited Ticker Symbol & Exchange: ASX: CUV, ADR: CLVLY Investor Relations Contact: Colin Mackie Investor Relations Contact Phone: 61 3 9660 4900 Web: www.clinuvel.com Date of Presentation: November 12, 2008 - 3:15PM Louis Rm Clinuvel Pharmaceuticals Limited (Clinuvel) is an Australian biopharmaceutical company developing a first-in-class photoprotective drug afamelanotide* (CUV1647) for use in a range of UV and light related skin disorders. Afamelanotide provides skin protection against UV radiation (UVR) as it stimulates the body's natural ability to produce eumelanin, the dark pigment of the skin which is known to have photoprotective properties. Clinuvel has identified five indications and has two Phase III trials underway, aswell as three Phase II trials. Clinuvel aims to have afamelanotide in the market by 2010. Company: Comanche Clean Energy Corp. Ticker Symbol & Exchange: OTCBB:CGYYF Investor Relations Contact: Todd M. Pitcher Investor Relations Contact Phone: 760-798-4938 Web: www.comanchecleanenergy.com Date of Presentation: November 10 at 10:20AM Comanche Clean Energy is a Brazil-based producer of ethanol and biodiesel from multiple feed-stocks in its own facilities and grows the majority of the sugar-cane feedstock that it requires for producing ethanol, creating a vertically integrated model. The company's customers for ethanol are fuel distributors and trading companies and its current biodiesel sales are to Petrobras, the Brazilian oil company. Comanche owns and operates two ethanol facilities and one biodiesel facility in Brazil. Through the six months ended, June 30, 2008, revenues were $22.1 million, up from $1.1 million reported for the same period last year. Company: CombinatoRx, Incorporated Ticker Symbol & Exchange: CRXX Investor Relations Contact: Gina Nugent Investor Relations Contact Phone: 617-301-7099 Web: www.combinatorx.com Date of Presentation: Nov. 10, 2008 CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. Company: Cougar Biotechnology, Inc. Ticker Symbol & Exchange: NASDAQ: CGRB Investor Relations Contact: Mariann Ohanesian Investor Relations Contact Phone: 310-943-8040 Web: www.cougarbiotechnology.com Date of Presentation: 11/12/2008 Cougar Biotechnology is a development stage biopharmaceutical company based in Los Angeles, California that in-licenses novel therapeutics and develops such therapeutics for the treatment of cancer. Our strategy is to license technologies that have previously been tested in clinical trials, enabling us to obtain an initial indication of the drug's safety and biological activity in humans before committing capital to the drug's development. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in a Phase III clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types. Company: CPEX Pharmaceuticals, Inc. Ticker Symbol & Exchange: NASDAQ : CPEX Investor Relations Contact: Laura Okpala Investor Relations Contact 617-583-1306, [email protected] Phone: Web: www.cpexpharm.com Date of Presentation: Tuesday November 11, 2008 2:30PM CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company primarily focused on the development of Nasulin(TM), an intranasal insulin drug, currently in Phase II trials for diabetes. CPEX has a proprietary drug delivery platform technology, CPE- 215(R), which allows it to expand its internal pipeline of products beyond Nasulin and generate revenue from partnering. CPEX has licensed applications of CPE-215 to Auxilium Pharmaceuticals, which launched Testim(R) in 2003. CPEX received royalties of $11.1 million in 2007 from sales of Testim. In addition, CPEX has a partnership with Serenity Pharmaceuticals for the development of a urology product incorporating its CPE-215 platform technology. Company: Crosshair Exploration & Mining Corp Ticker Symbol & Exchange: CXZ:AMEX, CXX:TSX Investor Relations Contact: Jennifer Richards Investor Relations Contact 604-681-8030 x.229 Phone: Web: www.crosshairexploration.com Date of Presentation: 11/12/2008 12:25 Crosshair is a leading junior exploration company focused on exploring and developing uranium in the Central Mineral Belt of Labrador, which is fast emerging as the next big uranium district in Canada. Crosshair is demonstrating the multi-deposit potential of the project by successfully developing and drilling several new uranium targets and currently controls four existing NI 43-101 compliant resources. Crosshair's gold and Volcanic Hosted Massive Sulphide projects in Newfoundland, are slated for a dividend spin-out to shareholders. Crosshair currently trades on the Toronto Stock Exchange (CXX:TSX) and the American Stock Exchange (CXZ:AMEX). Company: Cue Energy Resources Limited Ticker Symbol & Exchange: ASX : CUE Investor Relations Contact: Pauline Moffatt Investor Relations Contact Phone: 61 3 9670 8668 Web: www.cuenrg.com.au Date of Presentation: 11/11/2008 Cue is a small Australian independent, SE Asia and Australasian focussed, oil and gas exploration and production company. Cue has current oil production in Papua New Guinea and Indonesia with additional oil production beginning in New Zealand in late 2008. Gas production is expected to begin in Indonesia in 2009 and 2010. Appraisal drilling on other gas and oil discoveries is expected in 2009. Cue also holds a balanced portfolio of exploration areas in Australia, Papua New Guinea, New Zealand and Indonesia in which there are ongoing seismic and exploration drilling programs, and has interests in approximately 280 net BCF of contingent gas resources in Australia and Papua New Guinea. Company: Cyclacel Pharmaceuticals, Inc. Ticker Symbol & Exchange: CYCC - NASDAQ Investor Relations Contact: Corey Sohmer Investor Relations Contact Phone: 908-517-7330 Web: www.cyclacel.com Date of Presentation: 11/12/2008 Cyclacel is a biopharmaceutical business dedicated to discovery, development and commercialization of novel, targeted drugs to treat cancer and other serious disorders. Three orally-available drugs are in clinical development: sapacitabine, in randomized Phase 2 studies for the treatment of elderly acute myeloid leukemia, myelodysplastic syndromes and cutaneous T-cell lymphoma; seliciclib, in randomized Phase 2 studies for the treatment of non-small cell lung and nasopharyngeal cancers; and CYC116, in Phase 1 for solid tumors. Cyclacel's ALIGN subsidiary sells three products in the US treating the effects of radiation or chemotherapy in cancer patients: Xclair(R) Cream, Numoisyn(TM) Liquid and Lozenges. Company: Cytomedix Ticker Symbol & Exchange: AMEX:GTF Investor Relations Contact: Enrique Briz Investor Relations Contact Phone: 212/888-4848 Web: http://www.cytomedix.com Date of Presentation: Wednesday, Nov. 12, 2008 (2:25 pm) Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, including the AutoloGel(TM) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(TM) System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel(TM) System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti- inflammatory peptide, that has shown promise in pre-clinical testing, and for which the Company is currently preparing an Investigational New Drug (IND) application for the FDA. Company: Deer Consumer Products, Inc. Ticker Symbol & Exchange: DCPI (OTC BB) Investor Relations Contact: Ms. Yong MeiWang Investor Relations Contact Phone: 86 755-86028285 Web: www.deerinc.com Date of Presentation: 11/10/2008 14:25 Deer Consumer Products, Inc. is a US public company headquartered in China. Supported by more than 75 patents, Deer is a market leader in the design, manufacture and sale of home and kitchen electronics targeting the vast Chinese domestic consumer markets as well as customers in more than 40 countries worldwide. Deer's product lines include blenders, juicers, pressure cookers and other home electronics designed to improve home lifestyles in today's fast paced society. With more than 100 global and domestic clients including Black & Decker, Disney, Toastmaster, Home Depot and Wal- Mart, Deer has enjoyed rapid sales and earnings growth. Company: Delcath Systems, Inc. Ticker Symbol & Exchange: DCTH NASDAQ Investor Relations Contact: Strategic Growth International Investor Relations Contact Richard Cooper, 212.838.1444 Phone: Web: www.delcath.com Date of Presentation: 11/11/2008 Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents worldwide, including the U.S., Europe, Asia and Canada. Company: Derma Sciences Inc Ticker Symbol & Exchange: DSCI OTCBB Investor Relations Contact: Rudy Barrio @ Allen&Caron Inc Investor Relations Contact Phone: 212 691 8087 Web: www.dermasciences.com Date of Presentation: Wednesday, November 12, 2008 @ 2:00 Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in 2008. Company: DOR BioPharma, Inc. Ticker Symbol & Exchange: DORB: OTCBB Investor Relations Contact: Evan Myrianthopoulos Investor Relations Contact Phone: 609-538-8200 Web: www.dorbiopharma.com Date of Presentation: 11/10/2008 DOR BioPharma is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life- threatening complication of bone marrow transplantation. DOR anticipates market potential for orBec(R) for the treatment of GI GVHD to be approximately 60% of the more than 10,000 allogeneic hematopoietic cell transplantations that occur each year in the US, with similar numbers in Europe. Company: ECU Silver Mining Inc. Ticker Symbol & Exchange: TSX: ECU Investor Relations Contact: Christopher Haldane Investor Relations Contact 416.868.1079 ex.237 Phone: Web: www.ecu.ca Date of Presentation: 11/10/2008 ECU Silver Mining Inc. is focused on the exploration, development and mining of gold, silver and base metals at its Velardena District Properties in Durango, Mexico. The district is well known for its mining history and ECU holds three properties that include five historical mines. ECU has measured and indicated resources of 38 million ounces and inferred resources of 179 million ounces of silver equivalent. ECU's goal is to establish a significant polymetallic mineral resource in the heart of Mexico's mining district. Our mission is to become a pre-eminent silver and gold producer through the development of existing, and additional potential resources at Velardena. Company: eFuture Information Technology Ticker Symbol & Exchange: Nasdaq:EFUT Investor Relations Contact: Troe Wen Investor Relations Contact Phone: 86 1051650988 Web: www.e-future.com.cn Date of Presentation: 11/11/2008 eFuture Information Technology Inc. (NASDAQ: EFUT) is a leading provider of front-end supply chain management software and services in China. eFuture provides integrated software and services to manufacturers, distributors, wholesalers, logistics companies and retailers in China's front-end supply chain market, especially in the retail and FMCG industries. eFuture serves over 1,000 clients, including 15 Fortune 500 companies, over 900 retailers and over 200 distributors in China. eFuture is one of IBM's premier business partners in Asia Pacific and also partners with Oracle, Microsoft, JDA, Motorola and Samsung Network China. eFuture has over 600 employees and 20 branch offices across China. Company: Enable Holdings, Inc Ticker Symbol & Exchange: ENAB Investor Relations Contact: Ryan Calverley Investor Relations Contact 773.272.4414, Phone: [email protected] Web: www.EnableHoldings.com Date of Presentation: 11/10/2008 Enable Holdings Inc., is the world's leading excess inventory solutions company that links brand name sellers with customers around the globe. Enable Holdings, Inc. does this through its unique multi-channel asset-recovery solution that includes online auction platform solution uBid.com, fixed-price commerce solution RedTag.com, offline excess inventory solution RedTag Live!, business-to-business solution Dibu Trading Company, and private auction software solution Commerce Innovations. Brand name sellers are able to reduce distressed and excess inventories more efficiently and profitably than ever before, and achieve greater yield, while providing shoppers a connection to the world's most trusted brands at a value. Company: Endocyte, Inc. Investor Relations Contact: Vickey Buskirk Investor Relations Contact Phone: 765-463-7175 Web: www.endocyte.com Date of Presentation: 11/10/2008 Great progress has been made in the development of new drugs to treat cancer and other serious illness. However, these therapies are often administered at suboptimal doses because of their side effects on healthy tissues. The value of these therapies is further diminished because of the inability to predict if a patient will respond to a particular therapy. Endocyte is addressing both of these issues using a new "drug guidance" technology that is designed to deliver drugs directly to diseased cells. This guidance system is composed of a targeting ligand that attaches to a drug and then binds to receptors over-expressed on the membranes of diseased cells. Company: Energy Fuels, Inc. Ticker Symbol & Exchange: TSX: EFR Investor Relations Contact: Gary Steele Investor Relations Contact Phone: 303-974-2147 Web: www.energyfuels.com Date of Presentation: 11/11/2008 Energy Fuels is pursuing a mission to build a fully integrated uranium and vanadium production company through exploration, development, mining, milling & sales. The Company is a conventional, underground miner, utilizing low risk techniques of drilling, split shooting, and diesel haulage of waste and ore to the surface. Current technology is applied wherever it will increase productivity, lower cost, and improve grade control. Primary activities include: -- Developer and miner of southwest US U3O8 and V2O5 properties -- Prudent property acquisition to maintain full pipeline for production -- Property interests include six formerly producing U mines -- Aggressively refurbishing two of those mines to return them to production -- Licensing the 1000 tpd Pinon Ridge U/V mill, the first US mill for processing U to be built in 25 years Company: Epic Energy Resources Ticker Symbol & Exchange: EPCC - OTC BB Investor Relations Contact: Lisa Elliott Investor Relations Contact 713- 529-6600, [email protected] Phone: Web: www.1epic.com Date of Presentation: 11/11/2008 EPiC Energy Resources is a Houston based integrated energy services company. EPiC provides consulting, engineering, construction management, operations, maintenance, specialized training and data management services focused primarily on the upstream and midstream energy infrastructure. Services are provided through Pearl, a diversified engineering and energy services company; Carnrite, a management consulting company focused on providing strategic and operational consulting services to the broad energy industry; and EIS, a global training and data management services company. Epic's Pearl operations oversee projects primarily in the Rockies and has ongoing projects in the Middle East. Unconventional gas exploration and oil discoveries in the Rocky Mountains and other markets in the U.S. has driven strong demand for its services. Company:
Comments